iDose® TR (travoprost intracameral implant) 75 mcg

iDose TR is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

iDose TR is the first-of-its-kind, long duration, anchored intracameral procedural pharmaceutical therapy for the treatment of OAG or OHT. It delivers continuous prostaglandin analog therapy directly into the anterior chamber to help with long-term IOP control with proven safety and patient tolerability.

24/7 Adherence with iDose TR 

iDose TR is a paradigm-changing treatment. 

Designed to deliver continuous therapeutic levels of a proprietary formulation of travoprost intracamerally

Demonstrated long-term IOP control in two robust pivotal trials

Provides proven safety and patient tolerability

Learn More

Unprecedented Technology

iDose TR is composed of a biocompatible intracameral implant preloaded in a sterile, single-dose inserter.

  • Administers therapeutic levels of a highly-concentrated travoprost formulation
  • Proprietary membrane enables consistent, long-term elution performance
  • Anchored into scleral tissue to keep implant fixed and stable

Discover Innovation

Clinically Proven with Foundational IOP Control

In two pivotal trials, iDose TR achieved the pre-specified primary efficacy endpoint (non-inferiority to topical timolol through 3 months). 
At 12 months: 


of iDose TR subjects were completely free of IOP-lowering topical medication1

See the Efficacy Data

Enduring Safety Profile

The most commonly reported ocular adverse reactions (2% to 6%) were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperemia, and reduced visual acuity.2


  • No clinically significant endothelial cell loss
  • No periorbital fat atrophy
  • No serious corneal AEs
  • No DSAEK
  • No DMEK

idose TR is smaller than the center of the fingerprint

See the Safety Data


iDose TR Resources

HCP Resources
Get the facts and figures on the latest data, technology, and more to start integrating iDose TR into your practice.

Access Support
Overcome complex insurance coverage and reimbursement challenges with coding and billing

Patient Resources
Deliver patients access to insurance coverage resources, patient advocacy resources, and more.

Contact Us Today to Integrate iDose TR Into 
Your Practice

Complete the form to get started with offering iDose TR to your patients.

Request More Info

"*" indicates required fields

This field is for validation purposes and should be left unchanged.


  • iDose TR Phase 3 Clinical Trials, data on file, Glaukos Corporation.
  • iDose TR (travoprost intracameral implant) 75 mcg Prescribing Information. Glaukos Corporation. 2023.

Please Select Your Country


iDose® TR (travoprost intracameral implant)
Important Safety Information

Dosage And Administration

For ophthalmic intracameral administration. The intracameral administration should be carried out under standard aseptic conditions.


iDose TR is contraindicated in patients with active or suspected ocular or periocular infections, patients with corneal endothelial cell dystrophy (e.g., Fuch’s Dystrophy, corneal guttatae), patients with prior corneal transplantation, or endothelial cell transplants (e.g., Descemet’s Stripping Automated Endothelial Keratoplasty [DSAEK]), patients with hypersensitivity to travoprost or to any other components of the product.

Warnings And Precautions

iDose TR should be used with caution in patients with narrow angles or other angle abnormalities. Monitor patients routinely to confirm the location of the iDose TR at the site of administration. Increased pigmentation of the iris can occur. Iris pigmentation is likely to be permanent.

Adverse Reactions

In controlled studies, the most common ocular adverse reactions reported in 2% to 6% of patients were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperaemia, and reduced visual acuity.

Indications And Usage

iDose TR (travoprost intracameral implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Please see full Prescribing Information.

You are encouraged to report all side effects to the FDA. Visit, or call 1-800-FDA-1088.

You may also call Glaukos at 1-888-404-1644.